Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Pozycja w akcjach #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Cena akcji
$0.16328419
Kapitalizacja rynkowa
$204.14K
Zmiana (1 dzień)
4.35%
Zmiana (1 rok)
102.45%
Kraj
GB
Handel Fusion Antibodies plc (FAB)

Kategoria

Zyski dla Fusion Antibodies plc (FAB)
Zyski w Sep 2025 TTM: $-2.06M
Według najnowszych raportów finansowych Fusion Antibodies plc, obecny zysk firmy wynosi $-2.06M. W roku 2024 firma osiągnęła zysk w wysokości $-2.89M, wzrost w porównaniu do zysku z roku 2023, który wynosił $-3.53M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Fusion Antibodies plc od 2013 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$20.46B -992,770.77%
DK
$4.64B -225,408.48%
US
$5.23B -253,916.57%
US
$2.14B -103,830.35%
BE
$1.45B -70,512.80%
NL